Related Experiment Video
Updated: Sep 28, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal
Shyh-Min Huang1, Jing Li, Paul M Harari
1Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, Wisconsin 53792-0600, USA.
Abstract:
Tumor metastasis represents a complex multistep process that requires migration, invasion, and angiogenesis. In this study, we examined the impact of molecular blockade of the epidermal growth factor receptor on the invasive and metastatic capacity of human squamous cell carcinoma (SCC) of the head and neck using in vitro and in vivo model systems. Treatment with the anti-epidermal growth factor receptor antibody C225 attenuated the migration of SCC-1 tumor cells through a chemotaxis chamber in a dose-dependent manner. Incubation of SCC cells with 10-100 nM C225 for 4 h resulted in 40-60% inhibition of cell migration. Furthermore, in the presence of C225, the capacity of SCC-1 to invade across a layer of extracellular matrix (Matrigel) was significantly inhibited. Using an in vivo orthotopic floor-of-mouth xenograft model, locoregional tumor invasion of SCC-1 into muscle, vessel, bone, and perineural tissues was inhibited in C225-treated mice. This inhibition was additionally characterized by down-regulation in the expression of matrix metalloproteinase-9. These data suggest that inhibition of metastatic potential by C225 may be mediated via decreased migration and invasion of SCC cells. Regarding angiogenesis in vitro, we first studied human umbilical vascular endothelial cells, which established a capillary-like network structure (tube formation) in the presence of reconstituted Matrigel. Treatment with C225 reduced cell-to-cell interaction of human umbilical vascular endothelial cells, resulting in disruption of tube formation. The effect of C225 was additionally examined using an in vivo tumor xenograft neovascularization model of angiogenesis. Systemic treatment with C225 not only reduced tumor growth and the number of blood capillaries but also hindered the growth of established vessels toward the tumor. Taken together, these results provide evidence that C225 can suppress tumor-induced neovascularization and metastasis in SCC of the head and neck.
Insights
The anti-epidermal growth factor receptor antibody C225 effectively inhibits head and neck squamous cell carcinoma (SCC) metastasis by reducing tumor cell migration, invasion, and angiogenesis. This antibody shows promise in suppressing tumor growth and spread.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Tumor metastasis is a complex process involving migration, invasion, and angiogenesis.
- Head and neck squamous cell carcinoma (SCC) poses a significant clinical challenge.
- Targeting the epidermal growth factor receptor (EGFR) is a strategy in cancer therapy.
Purpose of the Study:
- To investigate the impact of EGFR blockade using antibody C225 on the invasive and metastatic capacity of human head and neck SCC.
- To evaluate the effects of C225 on tumor cell migration, invasion, and angiogenesis in vitro and in vivo.
Main Methods:
- Utilized in vitro models (chemotaxis chambers, Matrigel invasion assays) and in vivo orthotopic xenograft models.
- Assessed SCC cell migration and invasion following treatment with C225.
- Examined angiogenesis using human umbilical vascular endothelial cells and in vivo neovascularization models.
- Measured matrix metalloproteinase-9 (MMP-9) expression.
Main Results:
- C225 dose-dependently attenuated SCC cell migration and invasion through extracellular matrix.
- In vivo, C225 inhibited locoregional tumor invasion and down-regulated MMP-9 expression.
- C225 disrupted human umbilical vascular endothelial cell tube formation in vitro.
- Systemic C225 treatment reduced tumor growth, neovascularization, and vessel growth toward the tumor in vivo.
Conclusions:
- EGFR blockade with C225 significantly suppresses the metastatic potential of head and neck SCC.
- C225 inhibits tumor cell migration and invasion, potentially via MMP-9 down-regulation.
- C225 effectively suppresses tumor-induced angiogenesis, impacting tumor growth and spread.
- These findings support C225 as a therapeutic agent for inhibiting metastasis in head and neck SCC.
Related Concept Videos
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

